Oregon Health & Science University researchers reported that combining venetoclax with the CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia responses than venetoclax alone in ex vivo patient samples and mouse xenografts. Published in Cell Reports Medicine, the study screened 25 combinations and prioritized venetoclax+palbociclib for its ability to co‑target cell‑cycle and protein synthesis pathways and to overcome known resistance mechanisms. The team described mechanistic data showing combination‑specific pathway modulation and provided efficacy data across genetically heterogeneous AML samples. Authors propose clinical testing in venetoclax‑refractory AML and note the need for careful safety and dosing studies given overlapping hematologic toxicities.